Log in

NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Forecast & News

$4.49
-0.01 (-0.22 %)
(As of 03/29/2020 05:38 AM ET)
Today's Range
$4.03
Now: $4.49
$4.49
50-Day Range
$3.59
MA: $5.42
$7.20
52-Week Range
$2.25
Now: $4.49
$12.89
Volume33,981 shs
Average Volume31,934 shs
Market Capitalization$20.79 million
P/E RatioN/A
Dividend YieldN/A
Beta2.37
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
Read More
Eyegate Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEG
CUSIPN/A
Phone781-788-8869

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.69 million
Book Value$1.64 per share

Profitability

Net Income$-7,100,000.00

Miscellaneous

Employees11
Market Cap$20.79 million
Next Earnings Date5/13/2020 (Estimated)
OptionableNot Optionable

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.


Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

How has Eyegate Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eyegate Pharmaceuticals' stock was trading at $5.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYEG stock has decreased by 10.7% and is now trading at $4.49. View which stocks have been mosted impacted by Coronavirus.

When is Eyegate Pharmaceuticals' next earnings date?

Eyegate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Eyegate Pharmaceuticals.

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) posted its quarterly earnings data on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The specialty pharmaceutical company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.19 million. View Eyegate Pharmaceuticals' earnings history.

Has Eyegate Pharmaceuticals been receiving favorable news coverage?

Media stories about EYEG stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eyegate Pharmaceuticals earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutEyegate Pharmaceuticals.

Are investors shorting Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals saw a decline in short interest in March. As of March 13th, there was short interest totaling 16,900 shares, a decline of 56.0% from the February 27th total of 38,400 shares. Based on an average daily trading volume, of 26,000 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.4% of the company's stock are sold short. View Eyegate Pharmaceuticals' Current Options Chain.

Who are some of Eyegate Pharmaceuticals' key competitors?

What other stocks do shareholders of Eyegate Pharmaceuticals own?

Who are Eyegate Pharmaceuticals' key executives?

Eyegate Pharmaceuticals' management team includes the following people:
  • Mr. Stephen From, Pres, CEO & Director (Age 56)
  • Dr. Barbara M. Wirostko, Chief Medical Officer (Age 53)
  • Mr. Michael P. Manzo, VP of Engineering (Age 60)
  • Ms. Sarah Romano, Chief Financial Officer
  • Dr. MaryJane Rafii Ph.D., Consultant

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an IPO on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

Who are Eyegate Pharmaceuticals' major shareholders?

Eyegate Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.83%), Renaissance Technologies LLC (0.81%) and Virtu Financial LLC (0.32%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Brenda Mann, Morton Goldberg, Sarah Romano and Stephen From. View institutional ownership trends for Eyegate Pharmaceuticals.

Which institutional investors are buying Eyegate Pharmaceuticals stock?

EYEG stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Renaissance Technologies LLC, and Virtu Financial LLC. View insider buying and selling activity for Eyegate Pharmaceuticals.

How do I buy shares of Eyegate Pharmaceuticals?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyegate Pharmaceuticals' stock price today?

One share of EYEG stock can currently be purchased for approximately $4.49.

How big of a company is Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals has a market capitalization of $20.79 million and generates $2.69 million in revenue each year. The specialty pharmaceutical company earns $-7,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe. View additional information about Eyegate Pharmaceuticals.

What is Eyegate Pharmaceuticals' official website?

The official website for Eyegate Pharmaceuticals is http://www.eyegatepharma.com/.

How can I contact Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.


MarketBeat Community Rating for Eyegate Pharmaceuticals (NASDAQ EYEG)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  421 (Vote Outperform)
Underperform Votes:  352 (Vote Underperform)
Total Votes:  773
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Beta

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel